Search research articles
Contact Us
Filters
Showing results (221-230 of 239) with videos related to
Page
of 24
Sort By:
Lancet (London, England)
|
February 6, 2022
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
David M Gershenson, Austin Miller, William E Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Jung-Min Lee, Mark F Brady, Austin Miller, et al.
Gynecologic Oncology
|
May 6, 2023
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study
Tiffany Y Sia, William P Tew, Christopher Purdy, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 27, 2025
Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study
Angeles Alvarez Secord, Victoria Bae-Jump, Floor Backes, et al.
Obstetrics and Gynecology
|
January 12, 2019
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma
Peter G Rose, James J Java, Ritu Salani, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 23, 2009
Uterine Neoplasms. Clinical Practice Guidelines in Oncology
Benjamin E Greer, Wui-Jin Koh, Nadeem Abu-Rustum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2025
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancer
Robert L Hollis, Austin Miller, Heather A Lankes, et al.
Gynecologic Oncology
|
September 25, 2023
TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes
Karley Whelan, Mairead Dillon, Kyle C Strickland, et al.
Gynecologic Oncology
|
May 26, 2026
Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249
Lindsay M Kuroki, Danielle M Enserro, Heather A Lankes, et al.
The New England Journal of Medicine
|
November 14, 2019
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
Robert L Coleman, Nick M Spirtos, Danielle Enserro, et al.
Page
of 24
Search research articles
Search
Showing results (221-230 of 239) with videos related to
Sort By:
Page
of 24
Lancet (London, England)
|
February 6, 2022
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
David M Gershenson, Austin Miller, William E Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Jung-Min Lee, Mark F Brady, Austin Miller, et al.
Gynecologic Oncology
|
May 6, 2023
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study
Tiffany Y Sia, William P Tew, Christopher Purdy, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 27, 2025
Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study
Angeles Alvarez Secord, Victoria Bae-Jump, Floor Backes, et al.
Obstetrics and Gynecology
|
January 12, 2019
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma
Peter G Rose, James J Java, Ritu Salani, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 23, 2009
Uterine Neoplasms. Clinical Practice Guidelines in Oncology
Benjamin E Greer, Wui-Jin Koh, Nadeem Abu-Rustum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2025
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancer
Robert L Hollis, Austin Miller, Heather A Lankes, et al.
Gynecologic Oncology
|
September 25, 2023
TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes
Karley Whelan, Mairead Dillon, Kyle C Strickland, et al.
Gynecologic Oncology
|
May 26, 2026
Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249
Lindsay M Kuroki, Danielle M Enserro, Heather A Lankes, et al.
The New England Journal of Medicine
|
November 14, 2019
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
Robert L Coleman, Nick M Spirtos, Danielle Enserro, et al.
Page
of 24